Source:http://linkedlifedata.com/resource/pubmed/id/19936876
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2010-1-21
|
| pubmed:abstractText |
The efficacy and safety of high-dose chemotherapy with tandem autologous peripheral blood stem cell transplantation (auto-PBSCT) were evaluated in a multicenter clinical study of patients with advanced multiple myeloma. Eligible patients (n = 40) were consecutively enrolled in the phase I/II study and received 2-4 cycles of vincristine-adriamycin-dexamethasone regimen. The responding patients underwent PBSC harvesting following high-dose cyclophosphamide and filgrastim administration. The first auto-PBSCT (n = 32) following high-dose melphalan (200 mg/m(2)) was performed within 2 months of PBSC harvesting; the second auto-PBSCT (n = 28) was scheduled 3-6 months later. Treatment-related mortality was 2.5% (n = 1) throughout the protocol. Grade 4 nonhematologic toxicity occurred in 12.5 and 14.3% of the first and second auto-PBSCT patients, respectively. All but one patient (who died) achieved hematopoietic recovery. For the 28 patients completing the second auto-PBSCT, the results were favorable with a response rate of 65% (complete response rate = 27.5%, n = 11); the five-year progression-free survival and overall survival were 20.3 and 66.5%, respectively. In conclusion, high-dose chemotherapy with tandem auto-PBSCT is feasible and safe with a favorable response rate in treating advanced multiple myeloma in Japan.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1865-3774
|
| pubmed:author |
pubmed-author:ChouTakaakiT,
pubmed-author:GondoHisashiH,
pubmed-author:HaradaMineM,
pubmed-author:HinoNorihikoN,
pubmed-author:ImamuraYutakaY,
pubmed-author:KamimuraTomohikoT,
pubmed-author:MiwaAkiyoshiA,
pubmed-author:MiyataAkiraA,
pubmed-author:MizunoIshikazuI,
pubmed-author:SaburiYoshioY,
pubmed-author:SakaiAkiraA,
pubmed-author:SawamuraMorioM,
pubmed-author:ShimazakiChihiroC,
pubmed-author:ShinagawaKatsujiK,
pubmed-author:SunamiKazutakaK,
pubmed-author:TajimaFumihitoF,
pubmed-author:TakemotoYoshinobuY,
pubmed-author:TamakiShigehisaS,
pubmed-author:TsudaHiroyukiH
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
90
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
635-42
|
| pubmed:meshHeading |
pubmed-meshheading:19936876-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19936876-Combined Modality Therapy,
pubmed-meshheading:19936876-Dexamethasone,
pubmed-meshheading:19936876-Doxorubicin,
pubmed-meshheading:19936876-Humans,
pubmed-meshheading:19936876-Multiple Myeloma,
pubmed-meshheading:19936876-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:19936876-Survival Rate,
pubmed-meshheading:19936876-Transplantation, Autologous,
pubmed-meshheading:19936876-Treatment Outcome,
pubmed-meshheading:19936876-Vincristine
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Phase I/II study of tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation for advanced multiple myeloma.
|
| pubmed:affiliation |
Division of Hematology, Department of Internal Medicine, National Hospital Organization Okayama Medical Center, Kitaku, Okayama, 701-1192, Japan. kazusuna@pop12.odn.ne.jp
|
| pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|